Xtant Medical Holdings Inc. (XTNT) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, XTNT scores 65 out of 100, a letter grade of C, labeled "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:

• Fundamental Cash Engine (12/20): Per the Roarable RQD rating, this pillar reflects ROIC of 12.8% and an FCF yield of 24.95%. The FCF yield is high relative to the $0.29 price and $40.7M market cap, which can indicate that cash generation is strong relative to valuation, though the source does not explain the drivers behind it.
• Whale 13F Flow (12/20): Per the Roarable RQD rating, this pillar captures institutional accumulation and options positioning. The moderate score suggests institutional signals are present but not decisive.
• Insider Conviction (16/20): Per the Roarable RQD rating, this is the highest-scoring pillar, based on SEC Form 4 and Congressional PTR cluster flow. Insider activity is the strongest positive signal in the rating, though the underlying transaction detail is not provided in the source data.
• Macro Regime Fit (13/20): Per the Roarable RQD rating, beta is 1.0 and the score reflects sector sensitivity. A beta of 1.0 implies market-matching volatility, not elevated or dampened exposure.
• Forensic Balance Sheet (12/20): Per the Roarable RQD rating, this pillar cites an Altman Z-Score of 0.2, a Piotroski F-Score of 9/9, and Debt/Equity of 0.22. The Piotroski score is at its maximum, indicating strong fundamental-quality signals, while the Altman Z-Score of 0.2 is a distress-range reading that offsets much of that strength.

For a prospective investor, the rating signals a mixed picture: cash-flow metrics and insider signals support the stock, while the distress-range Altman score and the sub-dollar price warrant caution. Upside drivers would be sustained FCF generation and continued insider conviction; the main valuation tradeoff is that a low absolute price and small market cap coexist with weak bankruptcy-prediction metrics. The rating is analytical, not a recommendation.

Per the SEC financials, revenue grew from $91.3M in FY 2023 to $133.9M in FY 2025, and operating income moved from negative in FY 2023 and FY 2024 to $7.3M in FY 2025. Per the market data, gross margin is 62.9%, operating margin 5.4%, and net margin 0%. ROIC is 12.8%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 (distress range), the Piotroski F-Score is 9/9, and Debt/Equity is 0.22. Debt declined from $22.0M in FY 2024 to $11.0M in FY 2025 while cash rose to $17.1M.

• Market wire (YELLOW): A Yahoo! Finance Canada report on XTNT market action and institutional positioning, published 1h before the data timestamp.
• Risk Watch (RED): An ad-hoc-news.de report noting that short interest dropped to 143,564 shares.
• Market wire (YELLOW): A Benzinga pre-market mover roundup that includes XTNT.
• Market wire (YELLOW): A Simply Wall St article titled "Where Bioventus Goes After An 85% Climb," which is tagged to XTNT but concerns another company's performance.
• Risk Watch (RED): A report headlined "XTNT Q2 2026 Earnings: EPS Misses Estimates by 47.06% While Shares Rise 7.77%," sourced from a domain that is not a financial publisher. The headline itself is the only available content; the underlying figures are not independently confirmed in the source data.

The Butterfly supply-chain graph reports supply_chain as NONE, with no butterfly links and no proprietary signals.

• What drives the 24.95% FCF yield, and is FY 2025 free cash flow of $10.2M repeatable?
• Which specific Form 4 insider transactions and Congressional trades underpin the 16/20 insider conviction score?
• What explains the gap between the Altman Z-Score of 0.2 and the 9/9 Piotroski score, and what is the debt maturity profile behind the $11.0M debt figure?
• Are the reported FY 2025 net income ($0.0M) and EPS (N/A) figures complete, given that EPS and TTM EPS are both absent?
• What is the basis for the Q2 2026 EPS-miss headline, and can it be verified against a primary filing?